Member News
Dan Misutka Joins Gowling WLG’S Administrative Law Group
VANOUVER & ALBERTA — Gowling WLG is pleased to announce that Dan Misutka has joined the firm as a partner in the Administrative Law Group. He will split his time between… Read More
Ecosystem News | Member News
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer
Approval based on results from Phase 3 CROWN trial, showing LORVIQUA reduced risk of disease progression or death by 72% in newly diagnosed individuals compared to XALKORI® (crizotinib) NEW YORK… Read More
Member News
Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, Demonstrated Activity Against Omicron Variant in In Vitro Studies
KENILWORTH, N.J. & MIAMI — Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced data from six preclinical studies demonstrating that molnupiravir,… Read More
Member News
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis
VANCOUVER, B.C. — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has received… Read More
Member News
CHMP Issues Positive Opinion to Expand Jardiance (empagliflozin) Indication Based on Unprecedented Benefit in Adult Heart Failure Patients with Preserved Ejection Fraction
The positive opinion is based on the landmark EMPEROR-Preserved Phase III trial, which showed significant outcomes in patients with heart failure with left ventricular ejection fraction over 40%1 If approved,… Read More